Towards an intranasal influenza vaccine based on whole inactivated...


Update content

Title Towards an intranasal influenza vaccine based on whole inactivated influenza virus with N,N,N-trimethyl chitosan as adjuvant
Period 01 / 2007 - 12 / 2009
Status Completed
Dissertation Yes
Research number OND1319303
Data Supplier Website UU


Many scientists believe that the highly pathogenic H5N1 influenza virus (or other influenza viruses) can change into a human influenza virus that can potentially cause an influenza pandemic that could kill millions of people. Vaccines have been developed against the yearly circulating influenza strains, but the design of a vaccine against pandemic influenza is more difficult. One of the problems with pandemic influenza is that the exact strain is not known until the pandemic has started. From that moment the vaccine must be developed as fast as possible. In this project we are trying to understand what mechanisms determine the efficacy of a influenza vaccine and, based on the acquired insights, design the ideal pandemic influenza vaccine, which should be protective after a single dose, easy to produce, and easily administered. We will focus on the formulation of a nasal vaccine, because nasal administration has some clear advantages above conventional intramuscular injection. Local immunity is induced at the port of entry and nasal vaccines are needle free . This project involves the formulation and characterization of various colloidal vaccine carrier systems containing influenza antigens. These carriers (size 100-1000 nm) will be compared for their capability to present the antigens to the immune system to induce a protective immune response. Mice and ferrets will be used as animal models. From these initial studies we hope to find the ideal nasal vaccine carrier. This nasal vaccine will be further optimized by targeting the carriers to the antigen-presenting cells and addition of adjuvants.

Abstract (NL)

Het nasaal toedienen van een griepvaccin biedt voordelen boven een injectie in de spier, zoals een eenvoudige en pijnvrije toediening en mogelijk betere bescherming. Niels Hagenaars beschrijft in zijn proefschrift zijn onderzoek naar de ontwikkeling van een effectief nasaal griepvaccin. De resultaten van dit onderzoek geven aan dat geïnactiveerde griepvirussen gecoat kunnen worden met een positief geladen polymeer, genaamd TMC, waardoor deze vaccins in muizen veel effectiever worden. Verder beschrijft Hagenaars in zijn proefschrift de invloed die het type TMC heeft en hoe TMC werkt als versterker van de immuunrespons tegen een griepvaccin. De bevindingen van het onderzoek zijn veelbelovend voor de verdere ontwikkeling van deze vaccins.

Related organisations

Related people

Supervisor Prof.dr. W. Jiskoot
Supervisor Prof.dr. H. (Herman) Vromans
Co-supervisor Dr. E. (Enrico) Mastrobattista
Doctoral/PhD student Dr. N. Hagenaars


D23110 Infections, parasitology, virology

Go to page top
Go back to contents
Go back to site navigation